Rezolute

RZLT · NASDAQ

$3.70+$0.00 (+0.00%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $3.70

RZLT analyst rating

BuyConsensus of 9 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy9
Hold0
Underperform0
Sell0

12-month price target · 12 analysts

Average $9.28 (+150.9% upside)

Low: $6.06
Now: $3.70
High: $14.70

Upgrades and downgrades

The latest rating actions, newest first

RZLT analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Lake Street	Oct 6, 2026	Maintains	Buy	$9.00 → $12.00	14%
Citizens	Oct 6, 2026	Maintains	Market Outperform	$11.00 → $15.00	41%
Cantor Fitzgerald	Oct 6, 2026	Upgrade	Neutral → Overweight	—	28%
Lake Street	Sep 30, 2026	Initiates	Buy	$9.00	14%
Craig-Hallum	Sep 29, 2026	Upgrade	Hold → Buy	$4.00 → $7.00	31%
HC Wainwright & Co.	Sep 25, 2026	Maintains	Buy	$5.00 → $10.00	50%
Guggenheim	Jun 15, 2026	Maintains	Buy	$6.00 → $11.00	45%
Maxim Group	Jun 3, 2026	Maintains	Buy	$10.00 → $14.00	27%
Citizens	Jun 3, 2026	Upgrade	Market Perform → Market Outperform	$11.00	41%
Wedbush	Jun 3, 2026	Maintains	Outperform	$5.00 → $6.00	40%

The case for and against

Updated Oct 21, 2026

Bull case

Rezolute is viewed favorably because FDA feedback after the March Type B meeting and the agency’s request for an independent review of sunRIZE data suggest an unusually constructive regulatory posture, including a pre-BLA meeting path without an additional study request for cHI. Despite sunRIZE missing its primary endpoint, ersodetug still reduced hypoglycemia from baseline, and the OLE study showed continued glycemic and clinical benefit over 9 months to 2 years, supporting the drug’s biological activity. The investment case is further strengthened by the upLIFT trial, where seven patients have already met responder criteria and roughly nine of 16 are needed for success, indicating a high likelihood of a positive readout that could expand commercial opportunity.

Bear case

Rezolute is a high-risk clinical-stage biopharmaceutical company whose outlook is pressured by the possibility that RZ358 or other candidates fail efficacy endpoints, show safety or tolerability issues, or require additional FDA studies despite positive data. Its lead target, congenital hyperinsulinism, is an ultra-orphan market with existing therapies and potential new entrants, which could limit uptake even if approval is achieved. Financially, the company has a history of losses, reported a net loss of ($0.20) per basic and diluted share, and may need additional capital to fund studies or commercialization, while lowered OpEx assumptions also reduced 2027E EPS estimates.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.